FDA Clearance Tracker · P100042
APTIMA HPV ASSAY
Last checked: Nov 20, 2026Latest source record: Oct 28, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Oct 28, 2011
Approved
Time to decision
357 days
Received Nov 5, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P100042
- Device name
- APTIMA HPV ASSAY
- Applicant
- Gen-Probe Incorporated
- Applicant location
- San Diego, CA
- Received
- Nov 5, 2010
- Decided
- Oct 28, 2011
- Decision
- Approved
- Supplements
- 38 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE APTIMA HPV ASSAY.APTIMA HPV ASSAY INDICATIONS FOR USE:THE APTIMA HPV ASSAY IS AN IN VITRO NUCLEIC ACID AMPLIFICATION TEST FOR THE QUALITATIVE DETECTIONOFE6/E7 VIRAL MESSENGER RNA (MRNA) FROM 14 HIGH-RISK TYPES OF HUMAN PAPILLOMAVIRUS (HPV) IN CERVICAL SPECIMENS. THE HIGH-RISK HPV TYPES DETECTED BY THE ASSAY INCLUDE: 16, 18,31,33,35, 39,45,51,52,56,58,59,66, AND 68. THE APTIMA HPV ASSAY DOES NOT DISCRIMINATE BETWEEN THE14 HIGH-RISK TYPES. CERVICAL SPECIMENS IN THINPREP PAP TEST VIALS CONTAINING PRESERVCYT SOLUTIONAND COLLECTED WITH BROOM-TYPE OR CYTOBRUSH/ SPATULA COLLECTION DEVICES* MAY BE TESTED WITH THEAPTIMA HPV ASSAY. THE ASSAY IS USED WITH THE TIGRIS DTS SYSTEM. THE USE OF THE TEST IS INDICATED:I. TO SCREEN PATIENTS 21 YEARS AND OLDER WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US) CERVICAL CYTOLOGY RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TOCOLPOSCOPY. 2. IN WOMEN 30 YEARS AND OLDER, THE APTIMA HPV ASSAY CAN BE USED WITH CERVICAL CYTOLOGYTO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT.* BROOM-TYPE DEVICE (E.G., WALLACH PIPETTE) OR ENDOCERVICAL BRUSH/SPATULA.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OYB (Kit, rna detection, human papillomavirus).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Gen-Probe Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- APTIMA HPV ASSAYPMA supplement
P100042-S038 · Decided Feb 3, 2026 · 271 days after receipt · Panel Track
Device type: Kit, rna detection, human papillomavirus (OYB) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.